Ptc Therapeutics (PTCT) Cash & Current Investments (2012 - 2026)

Ptc Therapeutics' Cash & Current Investments history runs 15 years deep, the most recent figure standing at $1.9 billion for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 6.65% year-over-year to $1.9 billion in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 6.65% decrease from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 70.69% from the prior year.
• Cash & Current Investments retreated to $1.9 billion in Q1 2026 per PTCT's latest filing, from $1.9 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $2.0 billion in Q1 2025 and bottomed at $286.3 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $884.8 million (2024), against an average of $1.0 billion.
• Across the five-year window, Cash & Current Investments slumped 66.77% in 2022 and jumped 243.73% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $410.7 million in 2022, then surged by 113.47% to $876.7 million in 2023, then gained by 29.99% to $1.1 billion in 2024, then jumped by 70.69% to $1.9 billion in 2025, then fell by 2.72% to $1.9 billion in 2026.
• Per Business Quant, the three latest PTCT Cash & Current Investments figures stand at $1.9 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.7 billion (Q3 2025).